What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings?

The heat of the summer season brings a few more challenges for children living with diabetes. An expert speaks about how the ...

Continuous glucose monitors, small patches that provide 24-hour insight into concentrations of sugar in the blood, could be a ...

Abbott Laboratories (NYSE:ABT) ranks among the best low volatility stocks to buy according to analysts. RBC Capital ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.26 EPS, expectations were $1.26. Operator: Good morning, and thank you ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our ...

Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott's new head of diabetes business.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company today announced the Tandem t: slim X2™ insulin pump with Control-IQ+ automated insulin delivery technology ...

Abbott and MSD Pharmaceuticals announced a partnership to distribute oral anti-diabetic medicines, specifically sitagliptin, in India. The collaboration aims to leverage Abbott's widespread presence ...

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott ...